BioCentury | May 30, 2016
Clinical News

ASG-15ME: Phase I data

An open-label, dose-escalation, North American Phase I trial in 37 evaluable patients with metastatic urothelial cancer previously treated with >=1 chemotherapy regimen or who were unfit for cisplatin showed that once-weekly 0.5, 0.75, 1 and...
BioCentury | Jul 15, 2013
Company News

Seattle Genetics, Astellas deal

Seattle Genetics exercised a 2007 option from Astellas' Agensys Inc. subsidiary to co-develop and co-commercialize ASG-15ME . Agensys, which received an undisclosed exercise payment, submitted an IND for a Phase I trial of the antibody-drug conjugate...
BioCentury | May 6, 2010
Distillery Techniques

Technology: Disease models, member 5 (SLITRK5) knockout mice could be a new model for obsessive-compulsive disorder (OCD). Slitrk5...
...symptoms in the knockout animals compared with no treatment. Next steps include identifying mutations in SLITRK5...
Items per page:
1 - 3 of 3